David Alderman: ASH25 is Live
David Alderman, President and CEO at Molekule Consulting, shared on LinkedIn:
”Silence before the field ruptures again.
First thing you see walking into ASH25.
Black letters on white. Lobby reeks of fresh carpet glue.
Four days in Orlando will break frontline logic, erase durability curves, and force every franchise team to rewrite 2026–2030 tonight.
Hematology never sleeps in December.
Everyone else does.
If you’re here, you feel it in your chest already.
If you’re not, pay attention.
What leaves these halls this week will outlive the building.
We are already live in every lineage that pays the bills.
If today’s late-breakers just detonated your 2027 budget, find us before your competitor does.
ASH25 is live.”
All from ASH25 featured in Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women